Arthur L. Barry
About
Arthur L. Barry is a scholar working on Pharmacology, Molecular Medicine and Infectious Diseases.
According to data from OpenAlex, Arthur L. Barry has authored 117 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Pharmacology, 60 papers in Molecular Medicine and 47 papers in Infectious Diseases. Recurrent topics in Arthur L. Barry's work include Antibiotics Pharmacokinetics and Efficacy (66 papers), Antibiotic Resistance in Bacteria (60 papers) and Bacterial Identification and Susceptibility Testing (44 papers). Arthur L. Barry is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (66 papers), Antibiotic Resistance in Bacteria (60 papers) and Bacterial Identification and Susceptibility Testing (44 papers). Arthur L. Barry collaborates with scholars based in United States, Tanzania and Canada. Arthur L. Barry's co-authors include Peter Fuchs, Steven D. Brown, Ronald N. Jones, Ronald N. Jones, Clyde Thornsberry, Robert E. Badal, T L Gavan, E. Gerlach, Vera L. Sutter and Tracy D. Wilkins and has published in prestigious journals such as Clinical Infectious Diseases, The American Journal of Medicine and Journal of Clinical Microbiology.
In The Last Decade
Arthur L. Barry
113 papers receiving 1.7k citations
Peers
Arthur L. Barry
T L Gavan United States
D. Milatović Germany
Ronald N. Jones United States
J Duval France
Joseph M. Blondeau Canada
Deborah C. Draghi United States
Glenn A. Pankuch United States
Yigong Ge United States
Kevin Shannon United Kingdom
P. M. Waterworth United Kingdom
Citations per year, relative to Arthur L. Barry Arthur L. Barry (= 1×)
peers
T L Gavan
Countries citing papers authored by Arthur L. Barry
Since
Specialization
Citations
This map shows the geographic impact of Arthur L. Barry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur L. Barry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur L. Barry more than expected).
Fields of papers citing papers by Arthur L. Barry
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Arthur L. Barry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur L. Barry. The network helps show where Arthur L. Barry may publish in the future.
Co-authorship network of co-authors of Arthur L. Barry
This figure shows the co-authorship network connecting the top 25 collaborators of Arthur L. Barry. A scholar is included among the top collaborators of Arthur L. Barry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arthur L. Barry. Arthur L. Barry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Barry, Arthur L. & Steven D. Brown. (1999). Parameters for quality control of antimicrobial susceptibility tests of roxithromycin. Clinical Microbiology and Infection. 5(4). 233–234.
2.
Barry, Arthur L.. (1999). Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in North America. The American Journal of Medicine. 107(1). 28–33.
3.
Fuchs, Peter, Arthur L. Barry, & Steven D. Brown. (1999). Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalisfrom ten North American medical centres by three methods. Journal of Antimicrobial Chemotherapy. 43(1). 137–140.
4.
Fuchs, Peter, et al.. (1997). Reproducibility of broth microdilution and disk diffusion susceptibility tests of nine antimicrobial agents against Streptococcus pneumoniae ATCC 49619. Diagnostic Microbiology and Infectious Disease. 28(1). 27–29.
5.
Sewell, David L., Arthur L. Barry, Stephen D. Allen, et al.. (1996). Tentative interpretive criteria and quality control parameters for in-vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116)). Journal of Antimicrobial Chemotherapy. 37(1). 139–143.
6.
Fuchs, Peter, Arthur L. Barry, & Steven D. Brown. (1996). Survey of antimicrobial activity of four commonly used third generation cephalosporins tested against recent bacterial isolates from ten American medical centers, and assessment of disk diffusion test performance. Diagnostic Microbiology and Infectious Disease. 24(4). 213–219.
7.
Barry, Arthur L., et al.. (1993). RO 23–9424, a new cephalosporin 3'-quinolone: in-vitro antimicrobial activity and tentative disc diffusion interpretive criteria. Journal of Antimicrobial Chemotherapy. 31(1). 81–88.
8.
Barry, Arthur L.. (1990). Antistaphylococcal activity of amoxicillin and ticarcillin when combined with clavulanic acid evaluation of oxacillin-resistant and oxacillin-susceptible isolates. Diagnostic Microbiology and Infectious Disease. 13(5). 357–361.
9.
Jones, Ronald N. & Arthur L. Barry. (1989). In vitro evaluation of ramoplanin (A16686 or MDL62198): A new depsipeptide complex for potential topical use. Diagnostic Microbiology and Infectious Disease. 12(3). 279–282.
10.
Jones, Ronald N. & Arthur L. Barry. (1989). In vitro activity of Ro 23-9424, ceftazidime, and eight other newer beta-lactams against 100 Gram-positive blood culture isolates. Diagnostic Microbiology and Infectious Disease. 12(2). 143–147.
11.
Barry, Arthur L. & Ronald N. Jones. (1989). In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents. Journal of Antimicrobial Chemotherapy. 23(4). 527–535.
12.
Jones, Ronald N. & Arthur L. Barry. (1989). Detection of staphylococcal resistance to penicillinase-resistant penicillins. Diagnostic Microbiology and Infectious Disease. 12(5). 381–384.
13.
Fuchs, Peter, Ronald N. Jones, Arthur L. Barry, et al.. (1988). Effect of clavulanic acid on the susceptibility of clinical anaerobic bacteria to ticarcillin: A multicenter study. Diagnostic Microbiology and Infectious Disease. 9(1). 47–50.
14.
Jones, Ronald N. & Arthur L. Barry. (1988). Antimicrobial activity of MDL 19,592: An oral cephalosporin. Diagnostic Microbiology and Infectious Disease. 11(3). 159–162.
15.
Jones, Ronald N., Kenneth E. Aldridge, Arthur L. Barry, et al.. (1988). Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing. Diagnostic Microbiology and Infectious Disease. 10(4). 221–240.
16.
Barry, Arthur L. & Ronald N. Jones. (1988). Interpretative criteria for the agar diffusion susceptibility test with azithromycin. Journal of Antimicrobial Chemotherapy. 22(5). 637–641.
17.
Jones, Ronald N., Arthur L. Barry, Michael A. Pfaller, et al.. (1988). Antimicrobial activity of U-76,252 (CS-807), a new orally administered cephalosporin ester, including recommendations for MIC quality control. Diagnostic Microbiology and Infectious Disease. 9(1). 59–63.
18.
Fuchs, Peter, Ronald N. Jones, & Arthur L. Barry. (1987). Effect of β-lactamase inhibitors on the antimicrobial activity of cefoperazone, cefotaxime, and ceftizoxime against aerobic and anaerobic β-lactamase producing bacteria. Diagnostic Microbiology and Infectious Disease. 8(1). 61–65.
19.
Fuchs, Peter, Ronald N. Jones, Arthur L. Barry, et al.. (1986). In vitro evaluation of cefixime (FK027, FR17027, CL284635): Spectrum against recent clinical isolates, comparative antimicrobial activity, β-lactamase stability, and preliminary susceptibility testing criteria. Diagnostic Microbiology and Infectious Disease. 5(2). 151–162.
20.
Fuchs, Peter, Arthur L. Barry, Ronald N. Jones, & C Thornsberry. (1985). Evaluation of in vitro antibacterial activity of enoxacin: Comparison with other orally absorbed antimicrobial agents, proposed disk diffusion test interpretive criteria, and quality control limits. Diagnostic Microbiology and Infectious Disease. 3(3). 213–221.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by T L Gavan Breakdown of academic impact, for papers by D. Milatović Breakdown of academic impact, for papers by Ronald N. Jones Breakdown of academic impact, for papers by J Duval Breakdown of academic impact, for papers by Joseph M. Blondeau Breakdown of academic impact, for papers by Deborah C. Draghi Breakdown of academic impact, for papers by Glenn A. Pankuch Breakdown of academic impact, for papers by Yigong Ge Breakdown of academic impact, for papers by Kevin Shannon Breakdown of academic impact, for papers by P. M. Waterworth